Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
By Juanjuan Zhao, Q. Yuan, Haiyan Wang, Wei Liu, X. Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jin-xiu Li and 15 more. medRxiv, 2020
2,618 citations recorded by the source corpus.
Summary Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed. Findings Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006). Interpretation The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/871e8a46244daab786bcdf4bef762a385539f797
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. (2020, background): “With the majority of symptomatic cases developing detectable IgM and IgG antibodies between day 12 and 14 after disease onset respectively,(29) follow-up of asymptomatic cases may need to be extended to prevent incorrectly labelling a person as a case or infectious.”
- COVID-19: immunopathogenesis and Immunotherapeutics (2020, result): “A higher titer of total antibodies was independently associated with a worse clinical outcome of patients with COVID-19, and was significantly quicker than that of IgM and IgG.(38) In another study, within 19 days after symptom onset, 100% of patients tested positive for antiviral IgG.”
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability (2020, positive): “The potent S proteinspecific binding and neutralizing responses observed for COSCA3 are in line with earlier findings that severe disease is associated with a strong humoral response (32).”